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Abstract
Background. Emotional disorders are highly prevalent in primary care. We aimed to deter-
mine whether a transdiagnostic psychological therapy plus treatment-as-usual (TAU) is
more efficacious than TAU alone in primary care adult patients.
Methods. A randomized, two-arm, single-blind clinical trial was conducted in 22 primary
care centres in Spain. A total of 1061 adult patients with emotional disorders were enrolled.
The transdiagnostic protocol (n = 527) consisted of seven 90-min sessions (8–10 patients)
delivered over a 12–14-week period. TAU (n = 534) consisted of regular consultations with
a general practitioner. Primary outcome measures were self-reported symptoms of anxiety,
depression, and somatizations. Secondary outcome measures were functioning and quality
of life. Patients were assessed at baseline, post-treatment, and at 3, 6, and 12 months.
Intention-to-treat and per-protocol analyses were performed.
Results. Post-treatment primary outcomes were significantly better in the transdiagnostic
group compared to TAU (anxiety: p < 0.001; Morris’s d =−0.65; depression: p < 0.001; d =
−0.58, and somatic symptoms: p < 0.001; d =−0.40). These effects were sustained at the 12-
month follow-up (anxiety: p < 0.001; d =−0.44; depression: p < 0.001; d =−0.36 and somatic
symptoms: p < 0.001; d =−0.32). The transdiagnostic group also had significantly better out-
comes on functioning (d = 0.16–0.33) and quality of life domains (d = 0.24–0.42), with sus-
tained improvement at the 12-month follow-up in functioning (d = 0.25–0.39) and quality
of life (d = 0.58–0.72). Reliable recovery rates showed large between-group effect sizes (d >
0.80) in favour of the transdiagnostic group after treatment and at the 12-month follow-up.
Conclusions. Adding a brief transdiagnostic psychological intervention to TAU may signifi-
cantly improve outcomes in emotional disorders treated in primary care.
Trial Registration. isrctn.org identifier: ISRCTN58437086
Introduction
Emotional disorders – depression, anxiety, and somatoform disorders – are all highly preva-
lent in the community, imposing an enormous burden on society (Whiteford, Ferrari,
Degenhardt, Feigin, & Vos, 2015). In particular, depression and anxiety represent a global bur-
den that is even greater than the impact of chronic physical conditions (Vigo, Thornicroft, &
Atun, 2016). Given the large negative consequences of these disorders, it is clear that mental
health should be a major priority for all health systems (Patel et al., 2018). One approach to
improving access to evidence-based treatments would be to integrate mental health care into
the primary care setting (World Health Organization, 2018), where most patients with mild to
moderate emotional disorders are treated (Kovess-Masfety et al., 2007).
Many studies have shown that psychological therapy, mainly cognitive behavioural therapy
(CBT), is an effective treatment for emotional disorders in primary care (Cuijpers et al., 2019b;
Seekles et al., 2013). In recent years, several ambitious health care initiatives, such as the
Improving Access to Psychological Therapies (IAPT) project in the UK, have been carried
out to expand access to evidence-based psychological treatments for common mental disorders
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to a wider population. The results of the IAPT and similar pro-
jects show that these initiatives are cost-effective (Layard &
Clark, 2015) and highly beneficial for society (Clark, 2018;
Wakefield et al., 2020). The pioneering IAPT project provided
a model for similar international projects, such as those carried
out in Australia (Cromarty, Drummond, Francis, Watson, &
Battersby, 2016), Norway (Knapstad et al., 2018, 2020), and Canada
(Naeem, Pikard, Rao, Ayub, & Munshi, 2017). Nonetheless, sev-
eral barriers to dissemination of psychological treatments have
been identified (Harvey & Gumport, 2015), including the growing
number of disorder-specific treatment guidelines (Newby,
McKinnon, Kuyken, Gilbody, & Dalgleish, 2015), which may be
particularly relevant in primary care where individuals with emo-
tional disorders frequently present mixed symptoms attributable
to different mental health disorders, and primary care providers
often are not able to make a precise differential diagnosis due
to time and other constraints (Tylee & Walters, 2007).
In the past two decades, there has been a growing effort to
develop psychological treatments based on a transdiagnostic
approach, supported by evidence showing that many mental
disorders share the same psychological processes implicated
in the onset and maintenance of psychopathology (Aldao,
Nolen-Hoeksema, & Schweizer, 2010; Norton & Hope, 2005;
Patel et al., 2018). The available evidence suggests that transdiag-
nostic psychological therapy can be a highly effective treatment
for emotional disorders (Newby et al., 2015). This therapeutic
approach focuses on treating the common factors involved in
many emotional disorders such as cognitive biases (Beck, 2019;
Eysenck &Derakshan, 1997) and dysfunctional emotion regulation
strategies (Sakiris & Berle, 2019; Sloan et al., 2017), which are both
cognitive and behavioural (Naragon-Gainey, McMahon, &
Chacko, 2017). Most recent research has focused on individual
treatments – or, in some cases, virtual therapy (i.e. internet-based)
– but few studies have tested the efficacyof transdiagnostic group cog-
nitive behavioural therapy (TD-GCBT) (Chamberlain & Norton,
2013; Norton & Barrera, 2012). The available evidence, although
limited, suggests that the transdiagnostic group approach might
be a particularly useful, cost-effective treatment given the high
comorbidity among mental disorders, especially in primary care.
As in many other European countries, the National Health
System in Spain (Spanish acronym: SNS) is based on the princi-
ples of universal coverage, free access, and fairness. The SNS is
primarily funded by taxes. The system itself is centred around pri-
mary care centres, with the population assigned to a given centre
based on geographic proximity. Consequently, in this model, the
general practitioners (GP) and nursing staff act as the gatekeepers
to the SNS, except for emergency care. Primary care centres are
staffed by multidisciplinary teams comprised by GPs, paediatri-
cians, nurses, and administrative staff; some centres also have
social workers, midwives, and/or physiotherapists. The core
package of primary health care benefits compromises all health
care prevention, diagnosis, treatment and rehabilitation services,
including mental health. Unfortunately, in Spain, practically
none of the regions has mental health professionals on staff at
the primary care level. Rather, clinical psychologists working in
specialized care can periodically be sent to primary care centres
for mental health care issues, but this practice is very uncommon.
Therefore, given the minimal presence of clinical psychologists in
primary care, the provision of psychological therapy mainly relies
on referral to specialized care, for which waiting times are typic-
ally long. Thus, most patients with emotional disorders are treated
directly by their GPs, and this treatment tends to be medication-
centric, despite the recommendations provided by most clinical
guidelines. The use of psychotropic drugs (mainly antidepressants,
anxiolytics and hypnotics) has been increasing in Spain and their
use is currently higher than in many other European countries
(OECD, 2015).
In this context, we conducted a randomized controlled trial
(RCT) to compare TD-GCBT (7 sessions) plus treatment-as-usual
(TAU) to TAU alone in adult patients with emotional disorders in
the primary care setting. We hypothesized that TD-GCBT + TAU
would be more effective than TAU alone in reducing anxiety,
depression, and somatic symptoms, and that these benefits
would be sustained 3, 6, and 12 months after treatment finaliza-
tion. We further hypothesized that TD-GCBT + TAU would,
compared to TAU alone, reduce disability, improve quality of
life, and increase treatment satisfaction and that these benefits
would also be sustained over time.
Subjects and methods
Study design
The PsicAP trial was a multicentre, two-arm, single-blind, RCT.
Patients were recruited in the primary care setting within the
SNS with symptoms of an emotional disorder (depression, anx-
iety disorder, or somatization) and randomized to receive either
TAU alone (control group) or combined treatment involving
TD-GCBT + TAU.
Participants
Patients were recruited from 22 primary care centres in eight dif-
ferent regions in Spain (Andalusia, Basque region, Cantabria,
Castilla la Mancha, Galicia, Madrid, Navarra, and Valencia)
(Cano-Vindel et al., 2016). All patients who visited their GPs
with signs or symptoms of negative or unpleasant emotional pro-
blems, moderate depression, anxiety, or somatic symptoms with-
out any clear biological basis were considered candidates for study
inclusion. Patients receiving treatment with antidepressants,
anxiolytics, and/or hypnotics were also eligible and invited to par-
ticipate by their treating GP.
Recruitment
The GPs explained the study to potential participants during the
course of a routine clinical visit. Patients who agreed to participate
were provided with patient information sheet with written details
about the study and then asked to sign an informed consent form,
after which an initial session with a psychologist was scheduled.
At this visit, the study participants completed a battery of elec-
tronic questionnaires. The main study inclusion criteria were
(1) age between 18 and 65 years and (2) the presence of symp-
toms suggestive of an emotional disorder, whose presence was ini-
tially assessed with the Patient Health Questionnaire (PHQ;
Spitzer et al., 1999).
Exclusion criteria included any of the following severe mental
disorders: eating disorders; alcohol or substance abuse; bipolar
disorder; severe major depressive disorder; recent suicide attempt,
or other severe mental disorders diagnosed by the GP. The spe-
cific PHQ modules that assess for the presence of eating disorders
and alcohol abuse were used to detect these conditions and to
exclude patients with these disorders. Participants receiving psy-
chological treatment for any mental disorder were also excluded.
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Randomization and masking
A computer-generated allocation sequence was used to randomly
assign patients (1:1) to receive either TD-GCBT + TAU or TAU
alone. Study participants were contacted by email or phone to
inform them of their treatment allocation. A clinical psychologist
was assigned to lead a specific TD-GCBT intervention. Patients
allocated to TAU were instructed to return to their GPs for treat-
ment. None of the participants or clinicians was blinded to the
treatment allocation. However, in accordance with the single-
blind study design, the assessors involved in the pre- and post-
treatment assessment phases were blinded to the allocation and
did not participate in the interventions (TD-GCBT or TAU).
The GPs did not receive any information from the researchers
regarding baseline assessments, randomization, progress in the
intervention, or other outcomes. Medical records and notes




The TD-GCBT protocol (Cano-Vindel et al., 2016; González-
Blanch et al., 2018b) was a planned program consisting of seven
90-min therapy sessions held over a 12–14-week period in small
groups (8–10 patients) in the primary care centre. These sessions
were led by trained clinical psychologists, which were not part
of the primary care staff. In order to ensure the fidelity and
consistence of the TD-GCBT treatment at all participating sites,
all therapists were required to undergo an 8-h training program
in the treatment protocol. This training session was led by a
senior clinical psychologist. All therapists received a detailed,
session-by-session outline of the treatment. The therapeutic
approach was based on the transdiagnostic approach to emotional
disorders, which assumes that most emotional disorders share
several common factors (Aldao et al., 2010; Hofmann & Barlow,
2014), and that the onset and maintenance of emotional disorders
are due to dysregulated cognitive-behavioural emotion regulation
strategies (Aldao et al., 2010). Any participant who missed a train-
ing session was contacted by telephone by an assistant researcher
and offered to attend the next session. At the start of each training
session, the content of the previous session was briefly reviewed.
The TAU intervention consisted of regular consultations with
the treating GP, who assessed the patient’s physical and/or psy-
chosocial complaints. GPs were instructed to treat patients in
both arms in accordance with their best clinical judgment. In
general, these treatments involved the prescription of anxiolytics,
antidepressants, or hypnotics, and/or informal counselling/
support.
Primary outcomes
The primary outcome measure was the severity of symptoms of
emotional disorders (anxiety, depression, and somatic symp-
toms), which were assessed by the relevant PHQ modules
(Spitzer et al., 1999). The PHQ has been validated as a sensitive
and specific test to determine the presence of these disorders
based on the DSM-IV criteria. In a previous study that included
a subset (15%, n = 178) of the patients in the current trial, we
compared two PHQ modules to assess symptoms of anxiety
(Muñoz-Navarro et al., 2017a) and depression (Muñoz-Navarro
et al., 2017a) with clinical interviews (the gold standard) to valid-
ate these instruments in the present trial.
Symptoms of Anxiety (GAD-7). The presence of anxiety was
determined according to the Generalized Anxiety Disorder-7
scale (Spitzer et al., 2006). Total GAD-7 scores range from 0 to
21. For this trial, the cut-off for clinical significance on the
GAD-7 was set at ⩾10. Internal consistency of the scale was
good (α = 0.87). At this cut-off point, both sensitivity (0.87) and
specificity (0.78) were acceptable (Muñoz-Navarro et al., 2017a).
Mean scores were 12.3 (4.6) and the internal consistency of the
scale was good (α = 0.87).
Symptoms of Depression (PHQ-9). This PHQ module (Kroenke
et al., 2001) was used to detect depression with a cut-off point
of ⩾10. Total scores ranged from 10 to 23. Based on a previous
study of this cut-off score (Muñoz-Navarro et al., 2017a), partici-
pants who scored from 20 to 23 were assigned to undergo a
second-order assessment (interview with a clinical psychologist)
to confirm the presence of moderate or severe depression dis-
order. Based on this clinical assessment, the patients were
included or not in the trial (Cano-Vindel et al., 2016). The
mean score on the PHQ-9 was 13.6 (5.4) and the scale showed
a good internal consistency (α = 0.86). The most widely used
cut-off score in the literature (⩾10) was used as the threshold
for caseness, as this cut point presents a reliable balance between
sensitivity and specificity (Kroenke et al., 2001).
Symptoms of somatizations (PHQ-15). On the Spanish version of
the PHQ (Spitzer et al., 1999), patients rate 13 somatic symptoms
on a scale from 0 to 2, as follows: 0 (not bothered), 1 (bothered a
little), or 2 (bothered a lot). Two items from the depression mod-
ule (sleep and tiredness) are added and scored as follows: 0 (not at
all), 1 (several days), or 2 (more than half the days or nearly every
day). The reliability of this scale was acceptable (α = 0.80), with a
mean score of 14.0 (4.8). Somatic symptoms were assessed
according to the PHQ-15 sum score, with a maximum score of
30. Patient inclusion was based on an algorithm with the 13 som-
atic symptoms (patients with ⩾3 symptoms were classified as
‘bothered a lot’). A previous study used this algorithm to deter-
mine the sensitivity (78%) and specificity (71%) of the PHQ-15
(Kroenke et al., 2010).
Secondary outcomes
Functional Status. Secondary outcome measures included the
level of disability on daily life domains (work, social, and family
life) measured with the Sheehan Disability Scale (SDS; Luciano
et al., 2010). The internal consistency of this scale was good
(α = 0.80).
Quality of Life. Quality of life domains (physical, psychological,
social, and environmental) was evaluated with the World
Health Organization Quality of life Instrument-Abbreviated ver-
sion (WhoQoL-Bref; Lucas-Carrasco, 2012). Internal consistency
for all factors was acceptable (α > 0.70): (physical: α = 0.77; psy-
chological: α = 0.79; social: α = 0.70; environmental: α = 0.79).
Treatment Satisfaction. Treatment satisfaction for the groups was
assessed through a single question (‘Rate your satisfaction with the
treatment received’) with responses given on a 10-point scale ran-
ging from 0 (totally unsatisfied) and 10 (totally satisfied).
Statistical methods
Power and Sample size. To detect a minimally important effect
size of ⩾0.2 with an alpha error probability of 0.05 and a power
Psychological Medicine 3
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(1–β) of 0.80 using G*Power 3.1 for SPSS (Faul, Erdfelder, Lang,
& Buchner, 2007), a sample size of 394 participants per group
would be required. Anticipating a dropout rate of 25%, the neces-
sary sample size would be 525 participants per group. For all
results, we applied 95% confidence intervals (CI).
Main Analyses. For primary outcomes, we considered group dif-
ferences in anxiety (GAD-7), depression (PHQ-9), and somatic
symptoms (PHQ-15) comparing baseline and post-treatment
scores using a mixed-effect model. A mixed-effects model was
computed, including time and treatment group as fixed effects
and single participants as a random effect; group differences
were analysed after controlling for baseline characteristics: gender,
age, and treatment centre. For secondary outcomes, we similarly
checked between-group differences in the level of disability on
daily life domains (work, social, and family life) and quality of
life domains (physical, psychological, social, and environmental).
We performed an intention-to-treat (ITT) analysis that included
all randomized patients using the chained equations multiple
imputation procedure in the SPSS statistical software program,
with five imputations. The effect sizes of the treatment on primary
and secondary outcomes (mean scores) were calculated by apply-
ing Morris’s d statistic. Morris (2008) described an effect size for
the pre-post change (PPC) design, where the standardized effect
of the treatment is defined as the difference between groups in
mean PPC values, divided by the common standard deviation.
The formula for the Morris’ effect size is as follow: [δPPC =
(μT2 – μT1) − (μC2 – μC1)/σ], where μgt is the mean of group g
at time t, and σ is the standard deviation of the untreated popu-
lation. The main advantage of this formula is that it takes into
account the mean and standard deviation of the sample both at
the final assessment and at baseline, leading to a more represen-
tative effect size when the values differed from baseline.
Additional analyses: Recovery, reliable recovery, and deterior-
ation rates were calculated. The recovery index was defined as pre-
treatment scores above the threshold on any of the three scales
and below the threshold on all scales at either the post-treatment
or 12-month follow-up assessment. The reliable recovery rate was
calculated using a change score based on the standard deviation
(S.D.) and Cronbach’s alpha of each measure (as described in
the IAPT project) to account for scale measurement errors
(Clark et al., 2009). Thus, we used a change score of ⩾5 for the
GAD-7 and ⩾6 for the PHQ-9 and the PHQ-15. Among the
individuals who met the recovery criteria, individuals who
scored below the caseness threshold on all three measures after
treatment and showed reliable improvement on ⩾ one of the
three measures were considered to have achieved a reliable
recovery. By contrast, deterioration was defined as an increase
in the score on any of the three scales based on the criteria for
the scale in question. All statistical analyses were two-tailed;
given the multiplicity of comparisons for primary and secondary
outcomes, the final alpha level was set at 0.01. Effect sizes for
these analyses were calculated using Cohen’s d. In addition, a
per-protocol (PP) analysis for primary and secondary outcomes
was performed only in the patients who completed all follow-up
measurements.
Results
A total of 1691 patients assessed between 14 January 2014 and 30
July 2018, were considered potential candidates for participation
in this trial and were enrolled. Of those, 630 (37.3%) failed to
meet all inclusion criteria, leaving a total of 1061 patients
(62.7%) who met the trial inclusion criteria. These patients were
then randomized to the treatment (n = 527) or control (n = 534)
groups, and this sample (n = 1061) was used for the ITT analyses.
Of these 1061 patients, 316 in the TAU group and 314 in the
TD-GCBT + TAU group completed all post-treatment assess-
ments (drop-out rate: 40.8 and 40.4%, respectively). The final
1-year follow-up assessments were completed by 30 July 2019.
The study flow diagram is shown in Fig. 1.
Participants in the experimental group attended a mean of 4.5
(S.D. = 2.6) of the seven sessions; 67.7% of the participants
attended 4 or more sessions and were thus considered compliant.
The number of TD-GCBT sessions attended was significantly cor-
related with post-treatment outcome measures: PHQ-9 (r = −0.14;
p = 0.022), GAD-7 (r =−0.16; p = 0.008), and PHQ-15 (r = −0.16;
p = 0.007), indicating that treatment exposure was associated with
better outcomes.
The sociodemographic characteristics of the sample are shown
in Table 1. The most common patient profile was a married
woman in her early 40s (mean age, 43.6; S.D., 12.3), employed
part-time, earning less than €24 000 annually and presenting
symptoms of at least three common disorders (depression, anx-
iety, and somatic). There were no significant between-group dif-
ferences in TAU in terms of medications or dosage at the




On the ITT analyses, there were significant between-group differ-
ences in anxiety symptoms at all post-treatment time points ( p <
0.001), with better results in the TD-GCBT + TAU group, with
small to medium effect sizes (Morris’s d =−0.38 to −0.65). On
the PP analysis, significant differences were also observed on all
measures, but with medium to large effect sizes (Morris’s d =
−0.62 to −1.01). Table 2 and Fig. 2 provide detailed results on
these measures.
Depression symptoms (PHQ-9)
The ITT analyses revealed significant between-group differences
( p < 0.001) after treatment finalization and at all follow-up assess-
ments, with better outcomes in the TD-GCBT + TAU group, with
small to medium effect sizes (Morris’s d = −0.36 to −0.58). The
PP analyses also showed significant differences between the
groups on all measures, with medium to large effect sizes
(Morris’s d =−0.60 to −0.92). See Table 2 and Fig. 2 for more
details.
Somatization symptoms (PHQ-15)
Significant between-group differences were detected at all post-
treatment time points, indicating a greater reduction in somatic
symptoms in the TD-GCBT + TAU group ( p < 0.001). Effect
sizes ranged from small to medium (Morris’s d = −0.31 to
−0.40). The PP analyses showed significant differences between
the groups at all time points, with medium effect sizes (Morris’s
d =−0.49 to −0.65). Table 2 and Fig. 2 provide more details.
Recovery, reliable recovery, and deterioration rates
In the ITT analyses (data shown as values and 95% CI), recovery
rates for the TAU group at the post-treatment and 12-month
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assessments were 18% (14–22%) and 29% (22–36%), respect-
ively. For the TD-GCBT + TAU group, the recovery rates at
those same time points were 51.7% (46–57%) and 52% (45–
60%), yielding a between-group effect size of 0.76 (0.60–0.92)
and 0.51 (0.36–0.67), respectively. The proportion of indivi-
duals considered to have achieved a reliable recovery at the
post-treatment and 12-month assessments in the TAU group
was 13.3% (9–17%) and 11% (5–16%), respectively; in the
TD-GCBT + TAU group, the reliable recovery rates were
49.5% (44–55%) and 45% (37–48%), yielding a between-group
effect size of 0.84 (0.68–1.05) and 0.83 (0.67–0.99), respect-
ively. Deterioration rates at the post-treatment and 12-month
assessments were 14% (10–17%) and 12% (7−14%) for the
TAU group, and 3% (1–5%) and 3% (1–5%) for the
TD-GCBT + TAU, yielding a between-group effect size of
0.41 (0.26–0.57) and 0.35 (0.19–0.50), respectively. Similar
results were obtained on the PP analysis (data available on
request).
Fig. 1. Flow of participants through the trial.
Psychological Medicine 5
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Secondary outcomes
We observed (ITT analysis) a significantly greater decrease in the
treatment group v. controls on all the three disability dimensions
(work, social, and family life), with small effect sizes (Morris’ d =
−0.16 to −0.39). These differences were not significant at the
3-month follow-up but were significant at subsequent assessments
(months 6 and 12). A similar result was found on the PP analysis,
but with greater effect sizes, ranging from small to medium
(Morris’ d =−0.26 to −0.51) (Table 3). Small to medium effect
sizes (Morris’ d = 0.17–0.42) were found on the four quality of
life dimensions assessed, with some variations at months 3 and
Table 1. Demographics characteristics of sample
Characteristics Total (n = 1061)
Intention to treat sample Per protocol sample
TAU (n = 534)
TD-GCBT




Female 861 (81.1) 437 (81.8) 424 (80.5) 261 (82.6) 251 (79.7)
Male 200 (18.9) 97 (18.2) 103 (19.5) 55 (17.4) 64 (20.3)
Age group, years
⩽19 16 (1.5) 6 (1.1) 10 (1.9) 4 (1.3) 2 (0.6)
20–39 386 (36.4) 197 (36.9) 189 (35.9) 92 (29.1) 102 (32.4)
40–59 581 (54.8) 286 (53.6) 295 (56.0) 186 (58.9) 186 (59.0)
⩾60 78 (7.4) 45 (8.4) 33 (6.3) 34 (10.8) 25 (7.9)
Marital status
Married 513 (48.4) 248 (46.4) 265 (50.3) 159 (50.3) 177 (56.2)
Divorced 87 (8.2) 34 (6.5) 53 (10.1) 21 (6.6) 28 (8.9)
Widowed 29 (2.7) 14 (2.6) 15 (2.8) 10 (3.2) 6 (1.9)
Separated 58 (5.5) 37 (6.9) 21 (4.0) 18 (5.7) 10 (3.2)
Never married 212 (20.0) 102 (19.1) 110 (20.0) 56 (17.7) 51 (16.2)
Unmarried 162 (15.3) 99 (18.5) 63 (12.0) 52 (16.5) 43 (13.7)
Level of education
No schooling 11 (1.0) 7 (1.3) 4 (0.8) 3 (0.9) 3 (1.0)
Basic education 267 (25.2) 140 (26.2) 127 (24.1) 87 (27.5) 65 (20.6)
Secondary education 233 (22.0) 122 (22.8) 111 (21.1) 68 (21.5) 59 (18.7)
High School 262 (24.7) 123 (23.0) 139 (26.4) 79 (25.0) 94 (29.8)
Bachelor 242 (22.8) 119 (22.3) 123 (23.3) 70 (22.2) 84 (26.7)
Master/doctorate 46 (4.3) 23 (4.3) 23 (4.4) 9 (2.8) 10 (3.2)
Employment situation
Employed full-time 248 (14.7) 87 (16.3) 93 (17.6) 44 (13.9) 48 (15.2)
Employed part-time 633 (37.4) 209 (39.1) 183 (34.7) 122 (38.6) 115 (36.5)
Unemployed, in search of work 366 (21.6) 123 (23.0) 107 (20.3) 64 (20.3) 59 (18.7)
Unemployed, not looking for work 202 (11.9) 60 (11.2) 77 (14.6) 40 (12.7) 49 (15.6)
Temporary incapacity to work 129 (7.6) 32 (6.0) 41 (7.8) 25 (7.9) 26 (8.3)
Permanent incapacity to work 37 (2.2) 10 (1.9) 13 (2.5) 9 (2.8) 9 (2.9)
Retired 76 (4.5) 13 (2.4) 13 (2.5) 12 (3.8) 9 (2.9)
Level of income (per year)
Less than €12 000 euros 670 (39.6) 214 (40.0) 195 (37.0) 118 (37.3) 98 (30.5)
Between €120 000 and €24 000 690 (40.8) 215 (40.2) 218 (41.4) 129 (40.8) 139 (44.6)
Between €240 000 and €36 000 218 (12.9) 74 (13.9) 73 (13.9) 48 (15.2) 48 (15.7)
More than €36 000 113 (6.7) 31 (5.8) 41 (7.8) 21 (6.6) 30 (9.2)
TAU, treatment-as-usual; TD-GCBT, transdiagnostic group cognitive-behavioural therapy.
Results are presented as number and percentages.
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Table 2. Summary of between-group differences in primary trial outcome
Outcome measure
Intention to treat sample Per protocol sample
TAU TD-GCBT Difference TAU TD-GCBT Difference
No. M (S.D.) No. M (S.D.) Morris’ d p No. M (S.D.) No. M (S.D.) Morris’ d p
GAD-7
Baseline 534 – 527 – – – – 534 12.1 (4.7) 527 12.5 (4.6) – 0.264
Post-treatment 534 9.5 (5.4) 527 6.8 (4.7) −0.65 <0.001 316 10.2 (5.5) 315 6.0 (4.3) −1.01 <0.001
3 months 534 8.7 (5.3) 527 7.3 (5.0) −0.38 <0.001 238 8.9 (5.4) 273 6.7 (4.9) −0.62 <0.001
6 months 534 8.6 (5.4) 527 6.9 (5.1) −0.45 <0.001 204 8.8 (5.7) 229 6.2 (4.9) −0.78 <0.001
12 months 534 8.3 (5.7) 527 6.6 (5.4) −0.44 <0.001 180 8.7 (5.8) 208 5.8 (5.3) −0.91 <0.001
PHQ-9
Baseline 534 – – 527 – – – – 534 13.5 (5.4) 527 13.7 (5.3) – 0.443
Post-treatment 534 10.8 (6.4) 527 8.0 (5.7) −0.58 <0.001 316 11.5 (6.6) 315 7.0 (5.2) −0.92 <0.001
3 months 534 10.2 (6.4) 527 8.4 (6.0) −0.39 <0.001 238 10.3 (6.5) 273 7.8 (6.0) −0.60 <0.001
6 months 534 9.8 (6.4) 527 7.9 (6.1) −0.40 <0.001 205 10.0 (6.6) 228 7.3 (6.1) −0.75 <0.001
12 months 534 9.4 (6.3) 527 7.8 (5.9) −0.36 <0.001 180 9.7 (6.5) 208 7.1 (6.2) −0.61 <0.001
PHQ-15
Baseline 534 – – 527 – – – – 534 14.0 (4.8) 527 14.3 (4.9) – 0.388
Post-treatment 534 11.7 (5.2) 527 9.9 (5.4) −0.40 <0.001 316 12.1 (5.2) 315 9.1 (5.3) −0.65 <0.001
3 months 534 11.4 (5.1) 527 10.1 (5.3) −0.32 <0.001 238 11.7 (5.0) 273 9.5 (5.4) −0.49 <0.001
6 months 534 11.1 (5.3) 527 9.8 (5.6) −0.31 <0.001 205 11.5 (5.3) 228 9.2 (5.7) −0.59 <0.001
12 months 534 10.7 (5.6) 527 9.4 (5.6) −0.32 <0.001 180 11.7 (5.6) 208 8.8 (5.7) −0.57 <0.001
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6, and with medium effect sizes (Morris’ d = 0.55–0.72) at the
final assessment (Table 3). The PP results were similar, but
with larger effect sizes on almost all measures (Table 3).
Overall, patients in the treatment arm were more satisfied than
those in the TAU arm [9.75 (1.49) v. 7.72 (2.68)], which
represents a large effect size (Morris’ d > 0.90); however, this effect
size decreased at subsequent follow-ups from a large to a
medium-sized effect (Morris’ d = 0.65 to 0.51).
Discussion
The main finding of this RCT is that adding TD-GCBT to TAU
resulted in a greater reduction in the symptoms of emotional
disorders at all post-treatment time points (immediately after
treatment finalization, and at months 3, 6, and 12). The effect
sizes for the primary outcomes were large for anxiety symptoms
and medium for depressive and somatic symptoms.
Furthermore, these therapeutic effects were sustained throughout
the 12-month follow-up period, with small to large effect sizes.
Importantly, the reliable recovery rates showed large effect sizes
in favour of the experimental group at the immediate post-
treatment assessment and at the 12-month-follow-up. Patients
in the treatment group experienced a greater decrease in measures
of disability significantly, a greater improvement in the quality of
life and – as a consequence – higher treatment satisfaction imme-
diately (scores >9 on a 10-point scale) after treatment completion
and at the 12-month follow-up, thus supporting our secondary
hypothesis that TD-GCBT + TAU would yield superior results to
TAU alone on these measures. Of the patients in the TD-GCBT
arm, approximately 70% attended four or more of the seven ses-
sions, a finding that indicates the acceptability of the experimental
intervention.
These results are consistent with findings from previous
studies, confirming the greater efficacy and effectiveness of adding
CBT to TAU in the treatment of emotional disorders (Carpenter
et al., 2018; Cuijpers et al., 2019a). Some studies have found that
TD-CBT is highly effective in reducing the symptoms of anxiety
and depression (Newby et al., 2015), as evidenced by the studies
carried out by Norton and Barrera (Norton & Barrera, 2012)
and Chamberlain and Norton (Chamberlain & Norton, 2013),
both of which reported good results for TD-GCBT (mainly for
anxiety disorders). In the primary care setting, however, relatively
few studies have been conducted to evaluate individual or group
TD-CBT, with the notable exception of a recent pre-post observa-
tional study (Kristjánsdóttir et al., 2018) that assessed a 6-week
TD-GCBT intervention for adult patients with depression and/
or anxiety disorder. Reliable recovery rates in our trial were simi-
lar to those reported in other similar projects, such as the IAPT
project in the UK, which achieved reliable recovery rates close
to 50% on measures of anxiety and depression (Clark, 2018;
Wakefield et al., 2020) and slightly lower than those reported in
the Norwegian version of the IAPT (58.5%) (Knapstad et al.,
2020). However, it is worth noting that we applied stricter,
more conservative criteria, as we included three main outcomes
(anxiety, depression, and somatizations) v. only two (anxiety
and depression) in the IAPT programs. In fact, the between-group
effect size in our study (>0.80) was larger than that observed in
the Norwegian study (0.61). It is also important to emphasize
that reliable deterioration rates in the experimental arm in our
trial were notably lower than in the control group (3% v.
12–14%) as well as lower than the 5–10% deterioration rates com-
monly found in adult patients participating in clinical trials of
psychotherapeutic therapies (Lambert & Ogles, 2004).
In short, the findings of this large RCT support the efficacy of
adding TD-GCBT to TAU in the primary care setting to treat
patients with different emotional disorders. Our results show
that this combined approach improves symptomatology and
Fig. 2. Primary Outcomes at Baseline and Follow-up. TAU, treatment-as-usual;
TD-GCBT, transdiagnostic group cognitive-behavioural therapy. Error bars represent
standard errors.
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Table 3. Summary of between-group differences of secondary trial outcome
Outcome measure
Intention to treat sample Per protocol sample
TAU TD-GCBT Difference TAU TD-GCBT Difference
No. M (S.D.) No. M (S.D.) Morris’ d p No. M (S.D.) No. M (S.D.) Morris’ d p
Working lifea
Baseline 534 3.5 (3.1) 527 3.6 (3.2) – 0.600 534 3.5 (3.1) 527 3.6 (3.2) – 0.604
Post-treatment 534 3.0 (3.1) 527 2.6 (3.0) −0.16 0.002 316 3.1 (3.1) 315 2.4 (2.9) −0.26 0.002
3 months 534 2.7 (3.0) 527 2.4 (3.0) – 0.753 238 2.6 (3.0) 273 2.5 (2.9) – 0.814
6 months 534 2.7 (83.0) 527 2.1 (2.9) −0.22 0.001 204 2.8 (3.0) 229 1.9 (2.7) −0.32 0.001
12 months 534 3.1 (3.3) 527 2.4 (3.2) −0.25 <0.001 180 3.3 (3.3) 208 2.0 (2.7) −0.44 <0.001
Social lifea
Baseline 534 4.6 (3.0) 527 4.7 (3.0) – 0.965 534 4.6 (3.0) 527 4.7 (3.0) – 0.946
Post-treatment 534 4.1 (3.1) 527 3.2 (3.0) −0.33 <0.001 316 4.1 (3.1) 315 2.9 (2.8) −0.41 <0.001
3 months 534 3.5 (3.1) 527 3.2 (2.9) – 0.281 238 3.4 (3.2) 273 3.1 (2.9) – 0.291
6 months 534 3.4 (3.2) 527 2.7 (3.1) −0.27 <0.001 205 3.6 (3.2) 228 2.6 (2.8) −0.36 <0.001
12 months 534 3.8 (3.4) 527 2.9 (3.4) −0.33 <0.001 180 4.0 (3.3) 208 2.6 (3.1) −0.48 <0.001
Family lifea
Baseline 534 4.6 (3.1) 527 4.8 (3.0) – 0.437 534 4.6 (3.1) 527 4.8 (3.0) – 0.430
Post-treatment 534 3.9 (3.1) 527 3.1 (2.9) −0.33 <0.001 316 4.0 (3.1) 315 2.8 (3.1) −0.43 <0.001
3 months 534 3.5 (3.1) 527 3.1 (3.1) – 0.061 238 3.5 (3.1) 273 3.0 (3.0) – 0.067
6 months 534 3.6 (3.2) 527 2.7 (3.1) −0.36 <0.001 205 3.6 (3.1) 228 2.6 (2.7) −0.41 <0.001
12 months 534 3.8 (3.3) 527 2.8 (3.2) −0.39 <0.001 180 3.9 (3.3) 208 2.5 (2.8) −0.51 <0.001
Physicalb
Baseline 534 22.4 (4.3) 527 22.1 (4.3) – 0.327 534 22.4 (4.3) 527 22.1 (4.3) – 0.327
Post-treatment 534 23.2 (4.5) 527 24.7 (4.6) 0.42 <0.001 316 22.7 (4.6) 315 25.1 (4.7) 0.61 <0.001
3 months 534 23.5 (4.6) 527 24.2 (4.8) 0.23 0.017 238 23.2 (4.8) 273 24.4 (4.9) 0.34 0.004
6 months 534 23.6 (4.5) 527 24.3 (4.4) 0.23 0.008 204 23.1 (4.8) 229 24.7 (4.9) 0.44 0.001
12 months 534 24.2 (5.1) 527 26.4 (5.3) 0.58 <0.001 180 22.7 (5.1) 208 25.6 (5.3) 0.73 <0.001
Psychologicalb
Baseline 534 16.9 (3.8) 527 16.9 (3.8) – 0.578 534 16.9 (3.8) 527 16.9 (3.8) – 0.578
Post-treatment 534 17.7 (3.9) 527 19.2 (4.0) 0.39 <0.001 316 17.4 (4.2) 315 19.6 (4.0) 0.61 <0.001
3 months 534 18.1 (3.9) 527 18.9 (4.2) 0.21 0.001 238 18.0 (4.0) 273 19.3 (4.2) 0.38 <0.001
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Table 3. (Continued.)
Outcome measure
Intention to treat sample Per protocol sample
TAU TD-GCBT Difference TAU TD-GCBT Difference
No. M (S.D.) No. M (S.D.) Morris’ d p No. M (S.D.) No. M (S.D.) Morris’ d p
12 months 534 18.7 (4.4) 527 20.8 (4.6) 0.55 <0.001 180 18.3 (4.4) 208 20.2 (4.6) 0.54 <0.001
Socialb
Baseline 534 9.1 (2.4) 527 9.1 (2.4) – 0.915 534 9.1 (2.4) 527 9.1 (2.4) – 0.915
Post-treatment 534 9.4 (3.1) 527 9.8 (3.3) 0.17 0.024 316 9.2 (2.4) 315 10.0 (2.7) 0.31 <0.001
3 months 534 9.5 (2.3) 527 9.7 (2.3) – 0.110 238 9.3 (2.2) 273 9.8 (2.4) 0.21 0.014
6 months 534 9.5 (2.5) 527 9.7 (2.2) – 0.263 205 9.6 (2.5) 228 9.8 (2.2) – 0.467
12 months 534 9.7 (2.2) 527 11.1 (2.6) 0.58 0.005 180 9.3 (2.2) 208 10.0 (2.6) 0.29 0.005
Environmentb
Baseline 534 25.3 (4.5) 527 25.7 (4.6) – 0.143 534 25.3 (4.5) 527 25.7 (4.6) – 0.143
Post-treatment 534 25.7 (5.3) 527 27.2 (5.6) 0.24 <0.001 316 25.5 (4.7) 315 27.8 (4.8) 0.41 <0.001
3 months 534 26.1 (4.9) 527 26.9 (5.1) 0.09 0.012 238 26.1 (4.8) 273 27.5 (5.2) 0.15 0.001
6 months 534 26.5 (4.8) 527 27.1 (4.8) – 0.064 205 26.4 (4.8) 228 27.7 (5.0) 0.19 0.008
12 months 534 27.5 (5.0) 527 31.2 (5.3) 0.72 0.001 180 26.6 (5.0) 208 28.3 (5.3) 0.29 0.001
M, mean; TAU, treatment-as-usual; TD-GCBT, transdiagnostic group cognitive-behavioural therapy; S.D., standard deviation.
aDisability domains measured with the Sheehan Disability Scale.
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helps a large proportion of patients to recover while minimizing
the risk of deterioration. The brief group psychological interven-
tion applied in this study significantly improved several aspects of
functional impairment as well as the quality of life. This finding is
important given the growing demand among clinicians for treat-
ments that do not focus solely on symptom reduction (Gladis,
Gosch, Dishuk, & Crits-Christoph, 1999). The effect sizes of
these secondary outcomes were within the ranges reported in
published meta-analyses in terms of the effects of psychological
treatments on functioning and quality of life in patients with
emotional disorders (Kamenov, Twomey, Cabello, Prina, &
Ayuso-Mateos, 2016), with medium effect sizes for quality of
life, and small to medium effects for functioning. The modest
effects on these outcomes are consistent with the findings
reported in the meta-analysis conducted by Kamenov et al.
(2016), who concluded that psychological interventions appear
to have a greater positive effect on symptom severity than on
functioning and quality of life. Interestingly, we found that
some of the positive effects of treatment were not significant at
the 3- and 6-month follow-up assessments, suggesting that
changes in these variables may fluctuate after treatment. It is rea-
sonable to expect that changes in functioning and quality of life
take more time to take root than changes in symptoms, which
are more immediate. Nonetheless, it is important to emphasize
that the benefits observed in this trial for all dimensions of quality
of life and functioning were sustained 12 months after completion
of the therapeutic intervention.
Limitations
First, the effects of treatment were assessed with self-reported
measures, with the limitations inherent to such instruments.
Nevertheless, we employed only instruments that have been vali-
dated in the primary care setting. In addition, we also conducted
validity studies of these instruments in a subsample of our
patients (15% of the full sample) using semi-structured interviews
(the gold standard) for comparison to obtain the optimal cut-off
score for these tools (Muñoz-Navarro et al., 2017a, 2017b). We
also studied the validity of the PHQ modules in our primary
care sample, which showed excellent psychometric properties
(Cano-García et al., 2020; González-Blanch et al., 2018a;
Moreno et al., 2019). Another potential limitation is the high
attrition rate. Similar high attrition rates have also been reported
in other RCTs comparing psychological interventions with TAU
in primary care (Bortolotti, Menchetti, Bellini, Montaguti, &
Berardi, 2008). However, the high treatment compliance and
high level of treatment satisfaction support the feasibility and
acceptability of the TD-GCBT in this population. Besides the pri-
mary context, it seems likely that the high attrition rate was due to
the lack of sufficient research staff needed to implement a clinical
trial of this size, leading to a high rate of missing cases in both
groups. Even though this limitation may have affected the study’s
power to detect small effect sizes, the overall effect sizes for the
primary outcomes ranged from medium to large. Moreover, des-
pite the high dropout rate, no relevant clinical differences were
observed between the individuals who completed all assessments
and those who did not. Furthermore, the large number of GPs
involved in patient recruitment (>120 GPs from 22 centres)
also supports the value of the intervention for primary care pro-
viders. Another limitation is the use of TAU rather than sham
treatment to control for unspecific therapeutic factors, such as
therapist contact and expectancy effects. However, we purposely
selected TAU for the control arm to enhance the external validity
of the findings, as this reflects real-world clinical practice in
Spanish primary care settings. Although satisfaction with TAU
(7.7) was high and similar to that found in national surveys
(7.3) (Bernal-Delgado et al., 2018), future studies should compare
TD-GCBT to other group interventions such as relaxation ther-
apy. Finally, we do not have detailed information on the specific
interventions provided in the TAU arm for all participants; how-
ever, to prevent differences in TAU treatment, the GPs were
blinded to the treatment allocation and participants in the
TD-GCBT arm were specifically asked to avoid sharing any infor-
mation regarding the psychological therapy with their GPs.
Importantly, there were no significant between-group differences
in the number of GP visits or medications prescribed. Likewise, a
cost-efficacy and cost-utility study based on a subsample (n = 487)
of participants (Ruiz-Rodríguez, 2019) found no significant dif-
ferences at the 12-month follow-up in terms of costs associated
with GP visits (t =−0.21, p = 0.83), primary care nurse visits (t
= 0.63, p = 0.53), and medications (t =−0.27, p = 0.78). All these
data suggest that TAU was similar in the two groups during the
course of the study.
Conclusion
The PsicAP project is the largest mental health care clinical trial
ever conducted in Spain. Our findings provide compelling evi-
dence to support adding a brief TD-GCBT intervention to
usual care for the treatment of emotional disorders in primary
care. Importantly, the observed therapeutic benefits – symptom
reduction and better functioning and quality of life – were sus-
tained 1 year after treatment finalization. We believe this cost-
effective approach has the potential to dramatically improve the
clinical treatment of emotional disorders and could revolutionize
current models of care in the primary care setting in Spain.
Ultimately, our hope is that these findings will prompt health
authorities in Spain (and elsewhere) to consider the broad-based
implementation of this approach, expanding access to all primary
care centres, in line with the initiatives undertaken in other coun-
tries to improve access to psychological therapies.
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